Add to Calendar 8/26/2020 8:00:00 AM 8/27/2020 5:00:00 PM 2020 State of Possible Conference

Special thanks to our Platinum Sponsor Morgan Stanley

Registered attendees will receive an email with the subject line “Welcome to the State of Possible Conference 2020 - Event Access Link” from

The State of Possible Conference, MassBio's Annual Meeting, will now be hosted virtually on August 26-27, 2020. Featuring interactive networking and a groundbreaking viewer experience, this event will not be your average webinar.  

We will celebrate what’s possible in our industry and for patients today that wasn’t five or 10 years ago. The two-day event will draw over 600 industry leaders from Massachusetts and beyond to debate the most pressing challenges facing the life sciences to ensure we can continue this incredible success. Attendees will hear from the brightest minds through keynotes, panel discussions and 15-minute Possible Talks®, inspiring and engaging content in the style of a TED Talk.

"It's the Woodstock of Life Sciences, with all-star performers playing their greatest hits all on one stage.” – 2019 State of Possible Conference attendee
If you haven’t attended our State of Possible Conference before, it is the premier east coast life sciences conference. We have some of the brightest names in biotech talking about the issues impacting our industry, covering topics from the realities of precision medicine to advancing new drug targets faster.

To inquire about sponsorship opportunities, contact Laura Rudberg.

2020 State of Possible Conference Refund Policy

NOTE: MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning.
Online Conference, Link will be sent in advance of the event.
CEO, Rheos
As CEO, Barbara Fox brings more than 25 years of biopharmaceutical leadership expertise to Rheos Medicines. She joins the company from Tilos Therapeutics, a biotech company developing antibody-based therapies for oncology and immune-mediated diseases. Barbara served as Chief Executive Officer at Tilos and led the successful acquisition of the company by Merck in June of 2019. Previous positions include Entrepreneur-in-Residence at Partners Innovation Fund, Founder and Chief Executive Officer of Avaxia Biologics, Founder and Chief Scientific Officer of Recovery Pharmaceuticals, and VP, Discovery and Immunology at ImmuLogic Pharmaceutical Corp. Earlier in her career, Barbara was an Associate Professor of Rheumatology at the University of Maryland School of Medicine. She received her A.B. in Chemistry from Bryn Mawr College, her Ph.D. in Chemistry from the Massachusetts Institute of Technology and trained as a post-doc in Cellular Immunology at the National Institutes of Health.

Brought to you by